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Abstract
Background: Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain
inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of
various mediators that sustain the inflammatory network. Masitinib, a selective oral tyrosine kinase inhibitor,
effectively inhibits the survival, migration and activity of mast cells. This exploratory study assessed the safety and
clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive
MS (rfSPMS).
Methods: Multicenter, randomized, placebo-controlled, proof-of-concept trial. Masitinib was administered orally at 3
to 6 mg/kg/day for at least 12 months, with dose adjustment permitted in event of insufficient response with no
toxicity. The primary response endpoint was the change relative to baseline in the multiple sclerosis functional
composite score (MSFC). Clinical response was defined as an increase in MSFC score relative to baseline of > 100%.
Results: Thirty-five patients were randomized to receive masitinib (N = 27) or placebo (N= 8). Masitinib was
relatively well tolerated with the most common adverse events being asthenia, rash, nausea, edema, and diarrhea.
The overall frequency of adverse events was similar to the placebo group, however, a higher incidence of severe
and serious events was associated with masitinib treatment. Masitinib appeared to have a positive effect on MS-
related impairment for PPMS and rfSPMS patients, as evidenced by an improvement in MSFC scores relative to
baseline, compared with a worsening MSFC score in patients receiving placebo; +103%± 189 versus -60%± 190 at
month-12, respectively. This positive, albeit non-statistically significant response was observed as early as month-3
and sustained through to month-18, with similar trends seen in the PPMS and rfSPMS subpopulations. A total of 7/
22 (32%) assessable masitinib patients reported clinical response following 12 months of treatment (according to
the modified intent-to-treat population, observed cases) compared with none in the placebo group. The Expanded
Disability Status Scale remained stable for both treatment groups.
Conclusion: These data suggest that masitinib is of therapeutic benefit to PPMS and rfSPMS patients and could
therefore represent an innovative avenue of treatment for this disease. This exploratory trial provides evidence that
may support a larger placebo-controlled investigation.
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Background
Multiple sclerosis (MS) is an inflammatory condition
that damages the myelin of the central nervous system,
leading to neurologic impairment and possibly severe
disability. MS is characterized by chronic patchy inflam-
mation of the central nervous system with demyelination
and gliosis (scarring). It is thought that progression of
lesions in MS might have two components: an active im-
munological aspect and a degenerative aspect, although
it is unknown to what extent these are causally interre-
lated. Four principal courses of MS are currently defined
according to clinical characteristics; namely: Relapsing
Remitting MS (RRMS), Secondary Progressive MS
(SPMS), Primary Progressive MS (PPMS), and Progres-
sive Relapsing MS (PRMS). The disease typically pre-
sents as RRMS, with more than 50% of RRMS patients
entering a progressive phase (SPMS) following a highly
variable delay [1]. Approximately 10 to 15% of patients
present with PPMS, which is characterized by continu-
ous disease progression from the onset of disease, i.e.
without relapses and remissions, for which prognosis is
considered as poor due to the relatively rapid develop-
ment of advanced disability as compared with RRMS
[2,3]. In general, drugs used in the treatment of MS are
considered to act as immunomodulators, with the aim
to decrease relapse rate, modify relapses, and diminish
the accumulation of disability over time. Despite these
approved therapies, many of which require parenteral
administration, the unmet medical need in MS treat-
ment remains substantial, especially for the subpopula-
tions of PPMS and relapse-free SPMS (rfSPMS) for
which there are currently no treatments proven to slow
disease progression.
Masitinib mesilate, the investigatory drug of the
present study, is a selective tyrosine kinase inhibitor that
is particularly efficient in controlling the survival, migra-
tion and degranulation of mast cells (and thus indirectly
controlling the array of proinflammatory and vasoactive
mediators these cells can release), through inhibition of
essential growth and activation signaling pathways [4].
Indeed, promising results have been reported from
human clinical trials of masitinib in neurological and in-
flammatory disorders such as Alzheimer’s disease,
rheumatoid arthritis, asthma and mastocytosis [5-8].
Several findings support the hypothesis that mast cells,
which are found on both sides of the blood–brain bar-
rier (BBB) [9-11], actively participate in the pathogenesis
of MS and also experimental allergic encephalomyelitis
(EAE), an animal model of human demyelinating dis-
eases [11-14]. To this end, the ability and effect of masi-
tinib in the inhibition of mast cell function in MS was
explored using an EAE murine model considered to be a
model for all progressive forms of MS (see Additional
file 1: Preclinical data of masitinib in EAE). In summary,
treatment of mice with masitinib led to a significant re-
duction in disease relative to control mice. A masitinib
dose-dependent effect was also evident. Thus, molecules
able to inhibit the survival and/or activation of mast
cells may be able to control the symptoms and progres-
sion of MS or any related disease.
An exploratory study to assess the safety and clinical
benefit of masitinib in the treatment of PPMS and
rfSPMS patients was performed to investigate the hy-
pothesis that masitinib’s targeted inhibitory action on
mast cells may reduce the symptoms and progression of
MS as compared with a placebo.
Methods
Study design and eligibility criteria
This was a multicenter, double-blind, randomized pla-
cebo-controlled, exploratory phase 2a study of masitinib
in patients with PPMS or rfSPMS, treated over 12 months,
with an extension phase possible. Patients were rando-
mized to receive placebo or masitinib at an initial dose of
3 or 6 mg/kg/day, administered orally in two daily intakes.
A centralized randomization schedule for packaging and
labeling was generated and held by a third-party service
(Cardinal Systems, Paris, France). All participants and
study personnel were blinded to treatment allocated over
the study’s duration. For each patient, all efficacy and
safety parameters were recorded on the first day of treat-
ment (baseline), with monthly patient visits scheduled
for the first 3 months followed by visits once every
3 months thereafter for the duration of treatment. This
study was approved by the local central ethics committee
(Comité de Protection des Personnes Ile-de-France II)
and complied with the Declaration of Helsinki. Written
informed consent was obtained from all patients.
Patients aged 18 to 60, suffering from PPMS or rfSPMS
as diagnosed by the ‘McDonald criteria’ [15,16] and having
an Expanded Disability Status Scale (EDSS) score [17] be-
tween 2 to 6.5 with a progression > 1 within 2 years prior
to inclusion, were eligible for this study. The following
conditions were exclusion criteria: patients having SPMS
with relapse in the 2 years before inclusion; treatment with
interferon, glatiramer, oral or systemic corticosteroids,
adrenocorticotropic hormone, or an investigational agent
within 4 weeks of inclusion; and inadequate organ func-
tion defined via blood test levels.
Study drug
Masitinib and placebo were supplied as 100 or 200 mg
non divisible coated tablets (AB Science, France). Com-
position and dispensing of the masitinib and placebo
treatments were identical except for the amount of active
ingredient contained. Blinded dose adjustments of
1.5 mg/kg/day were permitted in the event of lack of re-
sponse and manageable toxicity. Following predetermined
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criteria, treatment could be temporarily interrupted and/
or the dosage decreased by 1.5 mg/kg/day in the event of
toxicity. To manage possible cutaneous rash a mandatory
concomitant treatment of cetirizine at 10 mg/day was
administered for the first 30 days of treatment. Other
permitted concomitant medications included analgesic
without anti-inflammatory action and oral narcotic anal-
gesic, although these were not to be taken on the day of a
study visit until all efficacy evaluations were completed.
Physical therapy, if performed at the time of study entry,
was provided under a stable and consistent regimen. The
following treatments were prohibited for the duration of
the study: administration of immunomodulating; immu-
nosuppressing; chemotherapy; paracetamol; and oral or
parenteral concomitant corticosteroids, except in the
event of protocol-defined demyelinating event for which
methylprednisolone at 1 g/day for 3 days was permitted.
Efficacy and safety assessment
Evaluation of treatment effect was based upon change in
clinical neurological functions. The primary endpoint
was the average change in multiple sclerosis functional
composite (MSFC) score [18] relative to baseline, with
clinical response defined as a >100% improvement (in-
crease) from baseline.
The MSFC score is a multidimensional, MS-specific
outcome measure, comprising of a timed 25-foot walk
(T25FW) test measuring leg function and ambulation, a
nine hole peg test (9-HPT) measuring arm and hand
function and a Paced Auditory Serial Addition Test 3
seconds (PASAT-3”) measuring cognitive function. The
MSFC was calculated as described in the National Mul-
tiple Sclerosis Society MSFC administration and scoring
manual [19]. Secondary endpoints included analysis of
the MSFC subcategories (namely, T25FW, 9-HPT and
PASAT-3”), and the expanded disability status scale
(EDSS) [17]. Safety was assessed throughout the study
via physical examinations, vital signs, clinical laboratory
evaluations and monitoring of adverse events (AEs), with
all AEs recorded regardless of causality.
The study design originally allowed for analysis accord-
ing to initial dose regimens, however a study amendment
closed the 3.0 mg/kg/day treatment arm when it became
apparent that insufficient response was observed at this
dose (regardless of treatment being received), and that
dose increases had been necessary for the vast majority of
patients entering the 3.0 mg/kg/day initial dose group.
Patients were therefore effectively pooled into a single
population receiving masitinib at a dose of 6.0 mg/kg/day.
Statistical analysis
Response analyses were performed on a modified intent-
to-treat (mITT) population, defined as all randomized
patients who received at least one dose of masitinib
(i.e. the intent-to-treat population) and who had under-
gone baseline assessment and at least one post-baseline
assessment of efficacy. Analysis was conducted accord-
ing to two possible datasets: the last observation carried
forward (LOCF) methodology (i.e. imputation of missing
values) was performed for all efficacy endpoints other
than MSFC response rates, which was based on those
patients having relevant data at the given time point
(i.e. observed cases). Descriptive statistics were used to
analyze the safety profile of the study population at the
time of study unblinding, after which date all placebo
treated patients were withdrawn and only masitinib
patients were able to continue treatment. Quantitative
variables were compared using a nonparametric Wil-
coxon rank sum test, and the Fisher’s exact test was used
for comparing categorical variables.
Results
Baseline characteristics and patient disposition
Figure 1 shows the trial profile. Thirty-five patients were
recruited and randomized from six centers in France,
corresponding to an intent-to-treat (ITT) population of
27 patients in the masitinib group and 8 patients in the
placebo group. Of these, 12 patients in the masitinib
group started treatment on 3 mg/kg/day before being
switched to 6 mg/kg/day (median time to switch was
2 months). Overall, patient baseline characteristics were
well balanced between the masitinib and placebo groups
(Table 1), as well as between the PPMS and rfSPMS sub-
populations (data not shown). The mean MSCF score at
baseline was slightly higher in the placebo group indicat-
ing better patient function as compared with the masiti-
nib group. As expected, the duration of disease was
longer in the rfSPMS population (median of 12.3 years)
as compared with the PPMS population (median of
2.3 years). A total of 30 patients were eligible for the
modified intent-to-treat (mITT) population consisting of
24 patients in the masitinib group (9 patients with PPMS
and 15 patients with rfSPMS) and 6 patients in the pla-
cebo group (3 patients each with PPMS or rfSPMS). Of
the five patients ineligible for the mITT population, two
had not undergone any post-baseline efficacy assessment
and three did not have a baseline PASAT-3” assessment
performed (see Figure 1). A total of 27/30 patients (90%)
from the mITT population, of which 22 patients
received masitinib treatment and 5 patients received pla-
cebo, could have completed at least 12-months of treat-
ment at the time of study unblinding, giving an
assessable population for response rate at month-12 of
27 patients. Three patients were excluded from the re-
sponse rate assessable population because they were still
on-going at the time of unblinding but had received less
than 12 months treatment.
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PPMS (n=8)
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Figure 1 Trial profile.
Table 1 Baseline characteristics (ITT population)
All N= 35 Masitinib N=27 Placebo N=8
Age (years) Mean± SD 48± 8 49 ± 9 47± 7
Min - Max 29–61 29–61 33–56
Weight (kg) Mean± SD 69± 19 67 ± 19 74 ± 20
Min - Max 43–140 43–140 54–108
Male N (%) 17 (49) 13 (48) 4 (50)
Duration of disease (years) Mean± SD 9.4 ± 7.4 9.5 ± 7.3 8.8 ± 8.4
Min - Max 0.2-28.6 0.2-28.6 1.5-25.6
MSFC score Mean± SD 0.0 ± 0.7 -0.1 ± 0.7 0.3 ± 0.8
9-HPT (seconds) Mean± SD 30± 9 30 ± 9 31± 12
PASAT-3” (correct answers) Mean± SD 31± 15 30 ± 15 36 ± 15
T25FW* Mean± SD N/A N/A N/A
EDSS score Mean± SD 4.9 ± 1.2 4.9 ± 1.2 5.0 ± 1.1
* The baseline average of the raw (seconds) timed 25-foot walk test was not applicable (N/A) because of the protocol deviation (see text for details).
MSFC=multiple sclerosis functional composite score. N=number of patients, intent-to-treat population. T25FW = timed 25-foot walk test. 9-HPT=nine hole peg
test. PASAT-3”=Paced Auditory Serial Addition Test 3 seconds. EDSS= expanded disability status scale. ITT= intent-to-treat.
Vermersch et al. BMC Neurology 2012, 12:36 Page 4 of 9
http://www.biomedcentral.com/1471-2377/12/36
Safety analysis
Assessment of safety was performed on all patients who
had received at least one treatment dose (i.e. the ITT
population, N=35), for the duration of treatment includ-
ing any extension period until unblinding. The proportion
of patients reporting at least one AE regardless of causality
was similar between groups; specifically 22/27 masitinib
treated patients (82%), of which only 19/27 patients (70%)
were suspected to have experienced a treatment-related
AE, and 6/8 placebo patients (75%). A summary of safety
is presented in Table 2. The majority of AEs were of mild-
to-moderate intensity and transitory, with the most fre-
quent AEs observed in patients receiving masitinib being:
asthenia (11/27 patients, 41%), rash (7/27, 26%), nausea
(6/27, 22%), edema (5/27, 19%), and diarrhea (3/27, 11%).
The frequency of severe AEs suspected to be treatment-
related (or not assessable), was 7/27 patients (26%), with
only rash recorded at a frequency >5% (2/27 patients, 7%).
Consistent with the known safety profile of masitinib,
hematological assessments showed a higher occurrence of
events (≥10% difference between treatment groups) for
masitinib treated patients as compared with placebo
patients for: leucopenia, 6/27 patients [22%] versus none,
respectively; and lymphopenia, 4/27 patients (15%) versus
none. In the masitinib group there was one severe case
(4%) of neutropenia reported, however, the majority of
other hematological events were of mild intensity (70%).
No severe decreases in white blood cell count,
hemoglobin count, platelet count, or lymphocyte count
were reported.
The median patient exposure to masitinib was 444 days
(range 12–631 days). At the cut-off date of study unblind-
ing, a total of 7/27 patients (26%) from the masitinib
group had exited the study due to AEs compared with
none from the placebo group. Of these, 3/27 patients
(11%) had reported severe AEs, including decreased neu-
trophil count (onset after 27 days of treatment with dur-
ation of 15 days), urticaria (onset after 17 days with
duration of 14 days), and hand-foot syndrome (Palmar-
Plantar Erythrodysesthesia) (onset after 31 days with
duration of 18 days). All cases resolved rapidly upon treat-
ment discontinuation. No deaths were reported.
Efficacy analysis
Unless stated otherwise, efficacy data from the mITT
population according to the LOCF dataset are presented
hereafter. A summary of response data at month-12 is
presented in Table 3. At month 12 the average of the
relative change in MSFC score with respect to baseline
was +103%± 189 (n = 24) versus −60%± 190 (n = 6) in
the masitinib and placebo groups, respectively. This
positive, albeit non-statistically significant response was
observable as early as month-3 and sustained through to
month-18 (see Additional file 2: Details of masitinib re-
sponse data). A total of 7/22 (32%) assessable masitinib
patients (i.e. according to the observed cases dataset)
reported clinical response following 12 months of treat-
ment compared with none in the placebo group. The
masitinib treated responders consisted of 2/8 (25%)
PPMS patients and 5/14 (36%) rfSPMS patients.
The increase from baseline in MSFC for the overall
population was mainly driven by T25FW and 9-HPT
scores (see Additional file 2: Details of masitinib response
data). The mean relative change in T25FW tended to in-
crease over the duration of treatment indicating deterior-
ation in performance; however, this was milder in the
masitinib group as compared with the placebo group (i.e.
5%±26 versus 26%± 55 at month 12, respectively). The
relative change in 9-HPT tended to decrease in the masiti-
nib group over the duration of treatment, indicating
improved function from baseline, whereas no improve-
ment was observed in the placebo group (i.e. -7%± 9 ver-
sus 0%±13 at month 12, respectively; corresponding to
absolute changes of approximately -2.2 versus 0.3 seconds,
respectively). The relative change in PASAT-3” tended to
increase throughout the study in both treatment groups
(e.g. 41%±111 versus 24%±30 at month 12 in the masiti-
nib and placebo groups, respectively; corresponding to ab-
solute mean changes of approximately 5 versus 7 correct
answers, respectively).
Table 2 Summary of safety data at time of unblinding (ITT population)
Number (%) of patients with Masitinib (N= 27) Placebo (N= 8)
At least one AE (all) 22 (81.5%) 6 (75.0%)
At least one AE (masitinib related) 19 (70.4%) N/A
Severe AE (all) 8 (29.6%) 1 (12.5%)
Severe AE (masitinib related) 7 (26.0%) N/A
Serious AE (all) 9 (33.3%) 2 (25.0%)
Serious AE (masitinib related) 4 (14.8%) N/A
Death (all) 0 (0.0%) 0 (0.0%)
AE leading to permanent discontinuation (all) 7 (26.0%) 0 (0.0%)
All= regardless of causality. Masitinib related = suspected or not assessable. N=number of patients, intent-to-treat population. N/A=not applicable.
ITT= intent-to-treat.
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Overall, EDSS scores remained stable throughout the
study in both treatment groups, with a mean change lower
than 0.5 in EDSS (see Additional file 2: Details of masiti-
nib response data). When analyzed by clinical course,
EDSS score at month 12 was stable in the PPMS popula-
tion in both treatment groups, whereas in the rfSPMS
population EDSS score remained stable in the masitinib
group but had increased in the placebo group by +1 point;
an increase indicating deteriorating patient function.
Discussion
Similar overall safety profiles were observed between the
masitinib and placebo groups, although there was a higher
incidence of severe and serious AEs associated with masi-
tinib treatment. The most frequent masitinib-associated
AEs were consistent with the known safety profile of tyro-
sine kinase inhibitors, notably rash, nausea, edema, and
diarrhea, which are generally considered manageable with
symptomatic treatments when of non severe intensity.
The majority of AEs leading to permanent discontinuation
in the present study were of non severe intensity, suggest-
ing therefore a fairly cautious investigator approach to
AEs or difficulties experienced in their management. As
rash was the leading cause of discontinuation in this and
other non-oncology masitinib trials (data not shown), fu-
ture studies might consider consulting a dermatologist on
matters of rash management and possible treatment inter-
ruption or dose adjustment prior to any decision on
discontinuation.
Although efficacy data did not produce statistically sig-
nificance differences between treatment groups, it does
suggest a positive effect of masitinib on MS-related im-
pairment and potential retardation of disease progres-
sion for both PPMS and rfSPMS patients. For example,
in patients treated with masitinib we observed an im-
provement in MSFC scores relative to baseline, com-
pared with a worsening MSFC score in patients
receiving placebo. These changes were mainly driven by
the T25FW and 9-HPT subscores, with the clinical
implications being that masitinib might slow down the
degeneration of lower limb function (as evidenced by a
milder deterioration of T25FW) and improve upper limb
function (as evidenced by improvement in 9-HPT).
However, no adjustments were made for learning effects
associated with some of the MSFC component mea-
sures, which may therefore have influenced these find-
ings [19]. Also, for progressive diseases such as PPMS,
the use of LOCF analysis is inclined to underestimate
functional deterioration. Conversely however, consider-
ing the number of positive MSFC clinical responses
achieved by masitinib patients (32%) compared with pla-
cebo patients (0%), it is unlikely that such effects had a
major impact on the overall results.
Initially, 35 patients were planned for a treatment
period of 36 months; however, this was amended to at
least 20 patients who had completed at least 12 months
of treatment. This protocol amendment, which effect-
ively unblinded the study early, was implemented in part
because even under blinded conditions it was probable
that some masitinib-treated MS patients were among
those showing positive response. In view of the pressing
medical need for an effective treatment in progressive
forms of MS, if this were the case then the primary ob-
jective to demonstrate acceptable safety and possible
therapeutic response, i.e. establish proof-of-concept,
would have been sufficiently accomplished, thereby en-
abling progression to the next development stage
(i.e. phase 2b/3). One negative consequence of this
reduced study population however, given the final data-
set, was that it precluded any demonstration of statistical
significance between the masitinib and placebo treat-
ment. A second factor in the decision to amend the
study population size was due to design factors and
minor protocol deviations that would have complicated
any definitive interpretation of efficacy, even if statistical
significance had been demonstrated. This included a
study amendment to close the 3.0 mg/kg/day treatment
arm because of lack of response, effectively pooling all
patients into the 6.0 mg/kg/day treatment arm. Also, it
became apparent that there was a minor protocol devi-
ation in the timed 25-foot walk (T25FW) test measuring
leg function and ambulation, which forms part of the
Table 3 Summary of response at month 12 with subgroup analysis according to type of disease and MSFC
subcategories (mITT population, LOCF method)
Placebo Masitinib
All (n = 6) All (n = 24) PPMS (n= 9) SPMS (n =15)
Relative change in MSFC score* Mean± SD -60%± 190 103%± 189 134%± 268 84%± 130
Relative change in T25FW Mean± SD 26%± 55 5%± 26 13%± 17 -1%± 29
Relative change in 9-HPT Mean± SD 0%± 13 -7%± 9 -5%± 7 -8%± 10
Relative change in PASAT-3” Mean± SD 24%± 30 41%± 111 19%± 66 55%± 131
Absolute change in EDSS score Mean± SD 0.3 ± 1.0 0.0 ± 0.5 0.1 ± 0.4 0.0 ± 0.5
* Change from to baseline. In the primary endpoint of MSFC an increase represents an improvement in MS-related impairment. mITT=modified intent to treat.
LOCF= last observation carried forward. MSFC=multiple sclerosis functional composite score. T25FW= timed 25-foot walk test. 9-HPT=nine hole peg test. PASAT-
3”=Paced Auditory Serial Addition Test 3 seconds. EDSS= expanded disability status scale.
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MSFC composite score. This test was misunderstood by
two test centers representing 7 and 10 patients of the
mITT population, respectively. One conducted the test
on 25 steps and the other on 25 meters instead of 25
feet. The resultant disparity between centers was statisti-
cally compensated for by individually calculating each
subpopulation’s T25FW z-score (i.e. with respect to units
of steps, meters or feet) with reference to its overall pa-
tient average, and then taking the average of these z-
scores for the overall T25FW z-score. This protocol de-
viation is expected to have had little or no effect on the
interpretation of the MSFC score because the z-score
(or standard score, a dimensionless quantity indicating
how many standard deviations an observation is above
or below the mean) allows direct comparison of observa-
tions from different units of measure.
The possible mechanisms of action by which masitinib
may be capable of inducing the observed positive thera-
peutic response in patients with progressive MS are
multifaceted. Although a topic of debate, there is grow-
ing evidence that the different courses of MS, i.e. relaps-
ing as opposed to relapse-free, are due to distinct
pathophysiologic processes. That is, RRMS and SPMS
are probably different stages of the same disease while
PPMS may imply different processes. Relapses are con-
sidered the clinical expression of acute inflammatory
focal lesions whereas progression is considered to reflect
the occurrence of demyelination, axonal loss and gliosis
[20]. This distinction in MS types appears to be reflected
by the unsuccessful treatment of PPMS with powerful
disease modifying drugs. In turn, this may relate to the
dominant cause of progression of disability in PPMS
being more strongly related to nerve cell death, in
addition to inflammation-induced neuronal damage
(swelling) commonly attributed to relapsing forms of
MS. As mentioned previously, there is good evidence in
support of mast cells being actively involved in the
pathogenesis of MS [12,13]. For example, sites of inflam-
matory demyelination contain cellular infiltrates with
mast cell accumulation in the brain and spinal cord, [21]
and the percentage of degranulated mast cells in the
central nervous system correlates with the clinical onset
of disease symptoms in acute EAE [22]. The contribu-
tion of mast cells to the pathological cascade of MS is in
part because they release large amounts of proinflamma-
tory mediators and therefore play a prominent role in
sustaining the inflammatory network of the central ner-
vous system [23]. The involvement of inflammation in
the development of brain injury in MS is well-established,
neurodegeneration being provoked in part by soluble
inflammatory mediators, with a significant correlation
existing between inflammation and acute axonal injury
[12]. Moreover, perivascular mast cells secrete pro-
inflammatory and vasoactive molecules that can regulate
the BBB’s permeability, a defective BBB being a common
finding that precedes clinical or pathological signs of MS
[14,24,25]. Additionally, it has been shown in vitro that
mast cell activation can lead to neuronal damage by indu-
cing astroglia to produce neurotoxic quantities of nitric
oxide (NO) [26]; NO being a molecule implicated in the
pathogenesis of MS, especially for those patients in pro-
gression [27,28]. It has also been reported that mast cells
can be a source of NO derivatives, which they synthesize
spontaneously or following activation, depending on their
subtype [29]. This evidence supports the notion that mast
cells, which can be found in close vicinity to neurons,
could influence the survival and functions of NO-
sensitive cells and through this mechanism participate in
the pathophysiology of chronic neurodegenerative dis-
eases of the nervous system. Additionally, it is plausible
that masitinib’s inhibitory action also effects the activa-
tion of dendritic cells, which are integral to the differenti-
ation of T helper cells and regulate T cell responses,
through inhibition of c-Kit and Lyn [30,31]. This hypoth-
esis may be of significance as recent genetic findings par-
ticularly implicate T helper cell differentiation in the
pathogenesis of MS [32].
Conclusions
Thus, masitinib’s anti-mast cell properties, and possible ef-
fect on dendritic cells, may be particularly well adapted to
the treatment of PPMS. A reduction of mast cell activity
via the inhibitory action of masitinib on c-Kit, Lyn and
Fyn tyrosine kinase activity, impacting both inflammatory
mediated and NO-mediated damage mechanisms, while
inhibition of dendritic cell activity may disrupt the signal-
ing pathways relevant to T helper cells. The findings of
the current study, within limitations inherent to such an
exploratory trial, suggest that oral masitinib was relatively
well tolerated and can be of therapeutic potential in the
treatment of MS, with positive responses observed in
some relevant measures of this condition. Moreover, this
positive action was observed in patients with PPMS and
rfSPMS, subpopulations for whom there are practically no
currently available treatments. Taken together with posi-
tive results from the complementary EAE mouse model,
this trial provides evidence that supports a larger placebo-
controlled investigation.
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